Subscribe To
NKTX / Why Nkarta Stock Is Soaring Today
NKTX News
By Zacks Investment Research
October 18, 2023
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis more_horizontal
By GlobeNewsWire
August 3, 2023
Nkarta to Participate at Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal
By Zacks Investment Research
June 28, 2023
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement amo more_horizontal
By The Motley Fool
June 27, 2023
Why Shares of Nkarta Are Slumping Tuesday
Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company execu more_horizontal
By GlobeNewsWire
June 26, 2023
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal
By GlobeNewsWire
April 12, 2023
Nkarta to Participate at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal
By InvestorPlace
April 11, 2023
3 Biotech Stocks to Watch for Potential Breakthroughs
Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory pro more_horizontal
By Seeking Alpha
March 26, 2023
Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down. more_horizontal